Search

What’s new in glaucoma? Clinical trials drive practice changes, surgical advancements gather pace

Rod McNeil reviews the latest developments in the treatment of glaucoma in the UK. Primary open-angle glaucoma (POAG), which accounts for over two-thirds of all glaucoma cases, has an estimated UK prevalence in 2017 of approximately 2% of people over...

Practice tips: Directions in cataract surgery services and preventing postcataract endophthalmitis

Future directions in the delivery of high quality cataract surgery services and approved intracameral prophylactic approaches to lowering the risk of postcataract infective endophthalmitis were debated by consultant ophthalmic surgeons in a recent London seminar, held at the Royal Society...

Streamlining cataract lists: how are you managing it?

Mr Jonathan Ross, in conversation with Ms Bita Manzouri, provides a personal perspective on challenges and opportunities shaping the future of cataract surgery services across the hospital eye service. Redesigning cataract pathways in response to COVID-19 Bita Manzouri: Over the...

My Top Five: Promising gene therapies for ocular conditions

Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

Are we short-sighted about myopia?

Worldwide prevalence of myopia has increased rapidly in recent years and has now reached epidemic levels, particularly in South-East Asia where prevalence is around 80% [1-4]. Myopia prevalence is also increasing in the United States and Europe where it is...

The role of inflammation in the pathophysiology of DMO

Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...